Lung Cancer Research

Lung Cancer Research

Johns Hopkins has been a leader in lung cancer research for decades. Among the investigations our researchers are pursuing is an inhaled targeted therapy that delivers its anticancer medicine using nanoparticles. Targeted therapy works by attacking only specific cancer cells, as opposed to traditional chemotherapy, which affects many kinds of cells, including healthy ones.

Additionally, in collaboration with the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, we are working on immunotherapy treatments for early-stage, locally advanced and advanced-stage lung cancer. Immunotherapy works by using the body’s own immune system to combat cancer. The National Comprehensive Cancer Network has written consensus guidelines identifying immunotherapy as being more effective than chemotherapy.

Members of our team are also pursuing population-based investigations aimed at improving access to prevention and treatment for all people, including looking at health disparities related to cancer and assessing the outcomes of various health delivery models.

Research Labs & Centers

Kimmel Cancer Center

Clinical Trials


Battling Cancer Using Epigenetics | Science: Out of the Box

Johns Hopkins surgeon and oncologist Malcolm Brock explains how we can fight cancer using epigenetic therapies. The epigenetic drug treatment changes cancer cells to be more like healthy cells, making them more susceptible to traditional cancer therapies like chemotherapy.

Dr. Ben Levy: The Mission is to Lead

Lung cancer specialist Benjamin Levy, M.D., has been named the new clinical director of medical oncology and medical director of thoracic oncology for the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in northwest Washington, D.C